**Supplementary Table S1. The Raw Rates of Response and Remission at Each Assessment Time Point**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Assessment Time** | **1-hour** | **2- hours** | **4- hours** | **24- hours** | **72- hours** | **1-week** | **2-weeks** | **3-weeks** | **4-weeks** |
| **Response, N (%)** | | | | | | | | | |
| Escitalopram + Placebo (N=14) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 1  (7.1) | 2  (14.3) | 7  (50.0) |
| Escitalopram + Ketamine (N=13) | 5  (38.5) | 7  (53.8) | 6  (46.2) | 5  (38.5) | 7  (53.8) | 7  (53.8) | 8  (61.5) | 10  (76.9) | 8  (61.5) |
| Number-needed-to-treat | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 9 |
|  | | | | | | | | | |
| **Remission, N (%)** | | | | | | | | | |
| Escitalopram + Placebo (N=14) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 0  (0.0) | 1  (7.1) | 1  (7.1) | 1  (7.1) |
| Escitalopram + Ketamine (N=13) | 2  (15.4) | 2  (15.4) | 0  (0.0) | 1  (7.7) | 2  (15.4) | 2  (15.4) | 3  (23.1) | 5  (38.5) | 5  (38.5) |
| Number-needed-to-treat | 7 | 7 | - | 13 | 7 | 7 | 5 | 4 | 4 |